2.
探讨骨髓微转移预后作用的主要临床研究
Major clinical studies of the prognostic value of DTC in bone marrow
| Study (Year) | Number of patients | Site of bone marrow harvest | Marker | Median follow up (month) | Frequency of occult disease | Prognostic relevance |
| NS: no siginificance; NA: not available. | ||||||
| Pantel et al (1996)[45] | 139 | Iliac crest and rib | CK2 | 39.0 | 83/139 (59.7%) | Earlier recurrence (P=0.028) |
| Hsu et al (2000)[25] | 96 | Iliac crest | AE1/AE3, MNF116, Ber-Ep4 | 20.2 | 21/96 (22.0%) | NS in 30 months OS or DFS (P=0.94; P=0.57) |
| Osaki et al (2002)[46] | 115 | Iliac crest | CK2 | 35.8 | 32/115 (28.0%) | NS in OS |
| Yasumoto et al (2003)[47] | 351 | Iliac crest | CK2 | NA | 112/351 (31.9%) | Worse OS with stage Ⅱ to Ⅲa (P=0.076); NS with stage Ⅰ |
| Nosotti et al (2008)[48] | 87 | Rib | Cytokeratin | 35.3 | 14/87 (16.0%) | Predictor of cancer recurrence (HR=2.09, P=0.002, 6); NS on DFS |
| Brunsvig et al (2008)[26] | 196 | Iliac crest | MOC31 (anti-EpCam) | 8.0 | 107/196 (55.0%) | NS |
| Ruffato et al (2009)[49] | 68 | Rib | MNF116 | 61.0 | 17/68 (25.0%) | Worse free from recurrence survival rate in stage Ⅰa and Ⅰ b |
| Rusch et al (2011)[18] | 1047 | Rib | Cytokeratin | 60.0 | 66/821 (8.0%) | NS |